Specialized Oncology Focus Global Med Source Inc operates as a niche CRO specializing in oncology and rare disease clinical trials, making it an ideal partner for pharmaceutical companies and biotech firms seeking expertise in these high-demand areas.

Recent Acquisition Advantage Having been acquired by Ergomed Plc for $25 million, MedSource benefits from increased financial stability and corporate resources, presenting growth opportunities for service expansion and joint ventures in clinical research.

Award Recognition Repeated recognition on the Inc. 5000 list highlights MedSource's reputation for quality and reliability, making it a trusted partner for organizations prioritizing high standards in clinical trial services.

Strategic Leadership Key hires from pharmaceutical giants like Eli Lilly demonstrate MedSource’s commitment to strong leadership and expertise in data management and operations, offering confidence to potential clients seeking experienced research partners.

Growth and Expansion Potential With a small team and revenue under $1 million, there is significant potential for scale with additional funding or strategic partnerships, especially by leveraging its oncology niche to attract pharmaceutical R&D investments and expand service offerings.